EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models
Artelo Biosciences, Inc. (NASDAQ:ARTL) on Monday announced new research published in the peer-reviewed Journal of Investigative Dermatology describing the positive effects of ART26.12 in both in vitro and in vivo psoriasis models.
The research shows results comparable to immunomodulatory drugs with known serious adverse events.
The research highlights ART26.12, Artelo's orally active, small-molecule inhibitor of Fatty Acid Binding Protein 5 (FABP5), and its potential ability to treat psoriasis.George Warren, PhD, Lead Author and Principal Scientist at Artelo, said, 'We are excited to share the results on this novel target in psoriasis. Our findings demonstrate that ART26.12 has effects comparable to powerful immunomodulators, while its unique pharmacology leads to a significantly distinct expression of proteins and lipids in the skin.'
Dr. Warren added, 'Pre-clinical IND-enabling studies with ART26.12, supported by a literature review of greater than 300 studies examining FABP inhibition, imply a low toxicological risk for ART26.12, which, if borne out in clinical studies, suggest FABP5 inhibition with an orally delivered small molecule may be an attractive, less costly, and safer approach for treating this debilitating chronic disease.'
A Phase 1 Single Ascending Dose study in healthy volunteers with ART26.12 has completed enrollment, and data announcements are expected in the second quarter of 2025.
The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN).
In addition to ART26.12 in CIPN, Artelo's extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders.
In January, Artelo Biosciences completed a safety review of the first cohort of eight healthy volunteers in the company's Phase 1 study of ART26.12.
In December, Artelo Biosciences announced the presentation of preliminary data on ART27.13, a benzimidazole derivative being studied for cancer-related anorexia.
Artelo is evaluating ART27.13 in the Phase 1/2 trial in cancer-related anorexia, which is currently enrolling Phase 2 of the study.
In Phase 1, ART27.13 was orally administered at 150 to 650 microgram doses.
The investigational drug was well tolerated, with only mild to moderate adverse events observed in a minority of participants.
At one month of treatment, two-thirds of participants showed evidence that the drug was impacting their weight loss, with either stabilization or reversal of weight loss associated with their cancer.
Phase 2 is accruing participants at a 650 microgram dosage with planned escalation at 4-week intervals up to a dose of 1300 micrograms per day. Initial data from the Phase 2 CAReS trial is anticipated by the end of Q2 2025.
Price Action: ARTL stock closed at $1.04 on Friday.
Read Next:UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
This article EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Amazon Signs 141,000 Square Foot We Work Lease In Silicon Valley Amid Relentless Expansion And Back To Work Mandate
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Amazon's (NASDAQ:AMZN) office expansion knows no bounds. Fresh from expanding its presence in New York, the tech giant announced it is growing its presence in Silicon Valley by teaming up with WeWork (NYSE:WE) to add 141,000 square feet of office space to accommodate its return-to-office mandate, CoStar News reports. The new offices are located at 4980 Great America Parkway in Santa Clara, California, in a building that Amazon will occupy in its entirety as part of its effort to have its workforce return to a five-day-per-week in-office work schedule. 'We're constantly evaluating our office footprint based on the needs of Amazon's businesses,' an Amazon spokesperson told CoStar News. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can WeWork has been a constant collaborator with Amazon, and the most recent deal follows similar arrangements the two companies have made recently, CosStar reports. At 330 W. 34th St. in New York and at 401 San Antonio Road in Mountain View, California, WeWork signed an office lease before Amazon moved in. 'So if we look at it and just take today's environment with all the uncertainty around tariffs and what's happening, who's prepared to commit to a 10- or a 15-year lease with $50 or $100 million spend?' WeWork CEO, John Santora, said of the arrangement with Amazon and other companies at a recent summit. 'You have to think about it. You have to think whether or not to invest that major capital in a market, at least through this short term. You have to step back,' he told Bloomberg. Trending: Invest Where It Hurts — And Help Millions Heal: While back-to-work mandates have been popular amongst many major corporations this year, Amazon has struggled to implement their's due to a lack of office space. Workers in Dallas, Phoenix, Atlanta and New York had their deadlines to return to the office pushed back four months while Amazon acquired more space. Amazon CEO Andy Jassy told employees in September that returning to an in-office work regimen was vital because 'collaborating, brainstorming and inventing are simpler and more effective.' 'If it's not for you, then that's OK. You can go and find another company if you want to. But for us, that's what we've decided is the best way to operate our company,' Amazon Web Services CEO Matt Garman said at a Wall Street Journal event in return-to-office push has not been without its complications, with parking space and commuting being among the complaints from former remote workers, the Journal reported. 'While we've heard ideas for improvement from a relatively small number of employees and are working to address those, these anecdotes don't reflect the sentiment we're hearing from most of our teammates,' a company spokeswoman told the Journal in February. 'What we're seeing is great energy across our offices.' On June 9 Pennsylvania Gov. Josh Shapiro announced that Amazon planned to invest 'at least $20 billion to establish multiple high-tech cloud computing and artificial intelligence (AI) innovation campuses across the Commonwealth of Pennsylvania.' The push would create 'at least 1,250 high-paying, high-tech jobs. Salem Township and Falls Township are the first communities identified as sites for these future campuses,' he said in a statement. It marks the largest capital investment in the commonwealth's history. Read Next: With Point, you can Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Image: Shutterstock This article Amazon Signs 141,000 Square Foot We Work Lease In Silicon Valley Amid Relentless Expansion And Back To Work Mandate originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Every Tesla Investor Should Keep an Eye on These 2 Numbers
Federal tax credits for electric vehicles could soon be eliminated. Another critical federal program is also at risk. These changes would only add to the mounting problems for Tesla. These 10 stocks could mint the next wave of millionaires › Tesla (NASDAQ: TSLA) has long been a volatile stock, but it's also become a very controversial name in recent months. Shares trade at a pricey valuation with a market cap of roughly $1 trillion, fueled by the promise of greater electric vehicle sales and a potential new robotaxi business. Yet sales growth for the company is struggling across many key geographies with CEO Elon Musk often making headlines for all the wrong reasons. If you're monitoring Tesla stock, here are two numbers you need to be tracking. A recent bill backed by President Donald Trump proposes eliminating tax credits for electric vehicles. These tax credits range from $4,000 to $7,500 for qualified vehicles. Right now, more than 90% of Tesla's sales come from just two models: The Model 3 and Model Y. Both qualify for federal tax credits, making them much more affordable for buyers. Surveys show that more than one-third of Tesla buyers wouldn't have purchased their vehicle without a tax credit. Monitor what happens to these figures closely. Will federal incentives drop to $0, or will they be reduced significantly? The fate of these tax credits is very unclear right now, but their elimination would likely further dampen Tesla's sales growth in the quarters and years to come. As troubling as the loss of the EV tax credit would be, there's another number to track that could be even more influential. Last quarter, Tesla posted a $409 million net profit. That profit was partially realized by $595 million in automotive regulatory credits -- accrued credits that Tesla sells to competitors that need to comply with emission standards. Most of these credits are likely earned under state programs, but some are generated from federal programs. If these programs are cut, Tesla will lose a critical revenue source with nearly 100% profit margins. With EV deliveries already declining, the loss of federal EV tax credits or automotive regulatory credits could put Tesla in an even more precarious position. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $368,190!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $37,294!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $653,702!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 9, 2025 Ryan Vanzo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy. Every Tesla Investor Should Keep an Eye on These 2 Numbers was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
NPWR Deadline: Rosen Law Firm Urges NET Power, Inc. (NYSE: NPWR) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of NET Power, Inc. (NYSE: NPWR, between June 9, 2023 and March 7, 2025. NET Power is a clean energy technology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that NET Power, Inc. (NYSE: NPWR) Misled Investors Regarding its Business Operations. According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) NET Power was unlikely to complete Project Permian (NET's efforts to develop its first utility-scale plant) on schedule, and the project was likely to be significantly more expensive than defendants had represented, because of, inter alia, supply chain issues and numerous site- and region-specific challenges; (2) accordingly, defendants' projections regarding the time and capital needed to complete Project Permian were unrealistic; (3) the increased time and capital needed to complete Project Permian were likely to have a significant negative impact on NET's business and financial results; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against NET Power, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by June 17, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
